Important note
This AI stock analysis for Walgreens is not up to date. Creating and accessing our AI stock Analysis (powered by our data and Chat GPT) is only available for our premium users. Sign up to get access today!
Walgreens - AI Stock Analysis
Analysis generated September 24, 2024
Walgreens Boots Alliance, Inc. is a global leader in retail and wholesale pharmacy. Established in 1901, the company operates a robust portfolio of retail pharmacy chains primarily located in the United States and Europe. The company's key business segments include Retail Pharmacy USA, Retail Pharmacy International, and Pharmaceutical Wholesale. Walgreens is committed to championing the health and well-being of the communities they serve, with over 9,000 retail stores operating under the Walgreens and Duane Reade banners in the U.S. alone.
Walgreens has shifted its focus in recent years to integrate its physical stores with digital and health services platforms, aimed at providing seamless, multichannel healthcare delivery. Partnerships, such as the strategic alliance with VillageMD, highlight Walgreens' efforts to expand into primary care services. However, the company faces stiff competition from other retail giants and online pharmacies, presenting both opportunities and challenges.
Fundamental Analysis
Walgreens reported revenue of $36.4 billion in the last quarter, which signifies a decrease of 1.52% from the previous quarter. This downtrend is concerning as it may indicate decreased sales or market share. However, compared to the same quarter last year, revenue increased by 3.14%, reflecting a positive year-over-year growth, suggesting long-term stability and market resilience.
The company's net income for the last quarter was $344 million, representing a staggering increase of 105.82% from the previous quarter. Compared to the same quarter last year, net income grew by 191.53%, indicating exceptional profitability. This surge in net income could be attributed to successful cost-containment measures or increased operational efficiency.
The last quarter's EBITDA stood at $994 million, up by 116.48% from the previous quarter and increased by 108.82% year-over-year. EBITDA growth is a key indicator of operational health and the company's ability to generate cash flows, highlighting Walgreens' improved financial performance.
Currently, Walgreens' Price-to-Earnings (P/E) ratio is 27.42. This relatively high value may indicate that the stock is overvalued, potentially marking investor optimism but also carrying a bearish outlook due to overvaluation concerns.
Technical Analysis
Today, Walgreens’ stock price is $8.72, reflecting a 15.34% decrease compared to a month ago and a 56.07% decrease from a year ago. These significant declines indicate bearish sentiment and a potential overcorrection in the market's valuation of the stock.
The stock's Simple Moving Average (SMA10) is currently 8.87, which is lower than the previous SMA10 of 8.92. This suggests a potential downward trend in price movement, aligning with the overall bearish trend. Relative Strength Index (RSI) stands at 64.1, indicating a neutral condition. An RSI near 70 could suggest overbought conditions, while a value near 30 may indicate oversold territory.
Alternative Data Analysis
From an alternative data perspective, Walgreens has 17,766 open positions as of the latest data, up by 32% in recent months. This increase in job postings suggests the company is in expansion mode, reflecting a potential for future growth. However, the business outlook has declined by 6% in the last couple of months, which is concerning and may indicate market skepticism.
Customer acquisition metrics reveal an estimate of 63 million visitors to their webpage with no significant change in the last few months. Mobile application downloads also remain unchanged at 7,800 users per day. In terms of customer engagement, Walgreens maintains a stable presence with 370,000 Instagram followers and 800,000 Twitter followers, though there are no significant increases in engagement, denoting a static presence.
AltIndex’s AI score, which integrates fundamental, technical, and alternative data analyses, assigns Walgreens a score of 43. This indicates a "hold" signal, suggesting that there are no significant buying or selling pressures at the moment.
Conclusion and Recommendation
In conclusion, Walgreens presents a mixed bag for potential investors. From a fundamental perspective, the company demonstrates strong year-over-year growth in revenue, net income, and EBITDA, indicating robust financial health. However, the high P/E ratio raises concerns about overvaluation.
Technical analysis paints a bearish picture with significant declines in stock price both on a monthly and yearly basis. The downward trend suggested by the SMA10 and neutral RSI condition further enforces this sentiment.
Alternative data reveals a potential for company growth driven by job postings but tempered by a decline in business outlook and static customer engagement metrics. The AI score's 'hold' recommendation aligns with these observations, suggesting caution.
Therefore, considering all these factors, a hold recommendation is prudent for current investors. Potential investors should closely monitor the stock for signs of stabilization or further fundamental improvements before making an entry.
Disclaimer: This AI stock analysis, generated by an experimental AI tool, is for informational purposes only and not financial advice. Information is based on publicly available data and may not always be accurate or current.
